Dyax is a biopharmaceutical company focused on the development and commercialization of products for unmet medical needs.
The company is driven by one unifying factor: to improve the lives of patients. Discovered and developed by Dyax, Kalbitor is approved in USA for the treatment of acute attacks of HAE in patients 12 years of age and older.
Dyax is dedicated to developing and commercializing treatments for HAE and is currently developing an investigational fully human monoclonal antibody inhibitor of active plasma kallikrein for the prevention of HAE attacks.
